ArticleMovement disorders clinical practice2020
Access and Use of Device-Aided Therapies for Parkinson's Disease in Denmark.
Article in Movement disorders clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Mechanisms of inequitable access to parkinson's disease care: a critical interpretive synthesis.International journal for equity in health · 2025Pooled it
- A systematic review of health disparities research in deep brain stimulation surgery for Parkinson's disease.Frontiers in human neuroscience · 2023Pooled it
- Tracking Motor Progression and Device-Aided Therapy Eligibility in Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson's disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study).Scientific reports · 2026Article
- Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study.Movement disorders clinical practice · 2026Observational
- Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021).BMJ neurology open · 2026Article
- Disparities in the Clinical Provision of Deep Brain Stimulation: A Systematic Scoping Review and Grounded-Theory Qualitative Analysis.Movement disorders clinical practice · 2025Article
- Cost of Quality of Life in Advanced Parkinson's Disease: Efficient Strategies for Disease Assessment.Revista de neurologia · 2025Article
- Perspectives on digital health and advanced treatment referral in Parkinson's care among Danish neurologists: a mixed methods study.Frontiers in neurology · 2025Article
- Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Accessibility of Device-Aided Therapies for Persons With Parkinson's Disease in Poland.Journal of movement disorders · 2024Article
- Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.Neurology and therapy · 2023Article
- Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.Journal of neural transmission (Vienna, Austria : 1996) · 2023Observational
- Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Trends and disparities in deep brain stimulation utilization in the United States: a Nationwide Inpatient Sample analysis from 1993 to 2017.Lancet regional health. Americas · 2023Article
- Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study.Brain sciences · 2023Article
- Personalized Medicine Approach in Treating Parkinson's Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Denmark's five regions, there is potential inequality in access to device-aided therapy (DAT) for Parkinson's disease (PD) based on structural or socioeconomic factors. It is unclear how long DAT is maintained and affects concomitant medication.
objectivesTo investigate access to DAT by comparing the proportion of patients with DBS, subcutaneous apomorphine infusion (SCAI), or levodopa/carbidopa intestinal gel (LCIG) in Danish regions 2008-2016 and describe demographics of patients, changes in use of comedication, and maintenance of DAT.
methodsThis work is a retrospective nationwide population-based registry analysis generated by combining various registries and statistics in Denmark.
resultsFrom 2008 to 2016, 612 patients started DAT. There were statistically significant differences in the number of patients starting DAT between the Capital Region (99.5 per 1,000) and both Central Jutland (66.6 per 1,000) and North Jutland (70.6 per 1,000;
conclusionsThere is unequal access to DAT in the Danish regions, and political and social considerations are warranted to address structural and socioeconomic causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.